Elizabeth Yeu Lin - 24 Jun 2024 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Role
Director
Signature
/s/ Scott Sieckert, Attorney-in-Fact
Issuer symbol
TARS
Transactions as of
24 Jun 2024
Net transactions value
$0
Form type
4
Filing time
25 Jun 2024, 18:24:12 UTC
Previous filing
24 Jun 2024
Next filing
06 Nov 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TARS Common Stock Options Exercise +3,350 +168% 5,350 24 Jun 2024 Direct F1
holding TARS Common Stock 12,040 24 Jun 2024 By 401(k) Plan
holding TARS Common Stock 15,866 24 Jun 2024 By Spouse's Roth IRA

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TARS Restricted Stock Units Options Exercise $0 -3,350 -100% $0.000000* 0 24 Jun 2024 Common Stock 3,350 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.
F2 Each RSU represents a contingent right to receive one share of the Company's common stock.
F3 RSUs granted on June 22, 2023, in connection with the Reporting Person's service as a non-employee director as of the Company's 2023 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.